8-K: Theriva Biologics Provides Corporate Update and Pipeline Overview

Theriva Biologics is advancing its oncolytic virus platform with a focus on VCN-01 and the Albumin Shield technology, targeting multiple cancer indications.

Summary

• Theriva Biologics is developing oncolytic viruses (OVs) for cancer treatment, with a focus on systemic administration.
• Their lead candidate, VCN-01, is in a Phase 2b clinical trial for first-line metastatic pancreatic cancer in combination with standard chemotherapy.
• VCN-01 has also shown promise in Phase 1 trials for retinoblastoma, head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC), both as a monotherapy and in combination with immunotherapies.
• The company's Albumin Shield platform aims to enhance OV delivery by protecting them from neutralizing antibodies.
• Theriva has a projected cash runway into Q1 2025 with $23.2M in cash as of December 31, 2023.
• The company is also developing SYN-004 for prevention of acute graft-vs-host disease and SYN-020 for potential indications including NAFLD/NASH, celiac, and radiation enteritis.
• The estimated treatment market for pancreatic cancer is ~$2.5B in 2022 and is projected to reach ~$7.0B by 2030.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data and a clear development plan. The company has a strong pipeline and is addressing significant unmet medical needs. However, the company is still in the clinical stage and faces risks associated with drug development.

Positives

• VCN-01 has shown promising efficacy in multiple cancer types, including pancreatic cancer, HNSCC, and retinoblastoma.
• The company's Albumin Shield technology has the potential to improve the delivery and effectiveness of oncolytic viruses.
• The company has a diverse pipeline of oncolytic virus candidates.
• Theriva has secured Orphan Drug Designation for VCN-01 in pancreatic cancer and retinoblastoma, which provides market exclusivity.
• The company has a seasoned leadership team with experience in oncolytic virus development and financial management.

Negatives

• The company is dependent on additional funding to advance its pipeline.
• The company's clinical trials are still ongoing, and there is no guarantee of regulatory approval.
• The company faces competition from other companies developing oncolytic viruses.
• Some adverse events were observed in clinical trials, including pyrexia, nausea, and vomiting.

Risks

• Clinical trials may not be successful, and product candidates may not receive regulatory approval.
• The company may not be able to secure sufficient funding to continue its operations.
• Competitors may develop more effective or less expensive treatments.
• The company may face challenges in manufacturing and commercializing its products.
• There are risks associated with the use of oncolytic viruses, including potential adverse events.

Future Outlook

The company plans to complete enrollment in the Phase 2b pancreatic cancer trial in H1 2024, discuss pivotal study design with regulatory agencies, and explore expansion opportunities in pancreatic cancer. They also plan to advance their Albumin Shield technology and other OV candidates.

Management Comments

• Management believes that oncolytic viruses are promising cancer therapeutics.
• Management expects to complete enrollment into the VIRAGE Study in H1 2024.
• Management is evaluating potential expansion opportunities in pancreatic cancer.

Industry Context

The oncolytic virus market is growing, with several companies developing similar therapies. Theriva's approach of using a stroma-degrading virus and an albumin shield is a differentiated approach in the field.

Comparison to Industry Standards

• CG Oncology's CG0070 is a competitor in the oncolytic virus space, targeting bladder cancer with a Phase 3 trial underway.
• Genelux's Olvi-Vec is another oncolytic virus in Phase 3 trials for ovarian cancer.
• Oncolytics Biotech's Pelareorep is in clinical trials for pancreatic cancer, similar to Theriva's VCN-01.
• Replimune's RP1 and RP2 are oncolytic viruses in clinical trials for melanoma and uveal melanoma.
• Theriva's VCN-01 has shown a higher response rate in Phase 1 trials (83.3% with chemotherapy) compared to the historical response rate of around 23% for chemotherapy alone in pancreatic cancer.
• The median overall survival of 20.8 months with VCN-01 plus chemotherapy in Phase 1 is also significantly higher than the historical median of 8.5 months with chemotherapy alone in pancreatic cancer.

Stakeholder Impact

• Shareholders may benefit from the potential success of the company's clinical trials and product development.
• Employees may benefit from the company's growth and success.
• Patients may benefit from new and effective cancer treatments.
• The company's success may have a positive impact on the healthcare industry.

Next Steps

• Complete enrollment in the Phase 2b pancreatic cancer trial.
• Discuss pivotal study design with FDA and EMA.
• Advance the Albumin Shield technology and other OV candidates.
• Present additional data at upcoming conferences.
• Seek additional funding and partnerships.

Key Dates

Keywords

oncolytic virus, VCN-01, pancreatic cancer, retinoblastoma, HNSCC, albumin shield, immunotherapy, clinical trial, orphan drug designation, cancer therapy